14Jul/13

Dr Reddy's Labs scrip outperforms BSEHC, touches yearly high of – pharmabiz.com


pharmabiz.com

Dr Reddy’s Labs scrip outperforms BSEHC, touches yearly high of
pharmabiz.com
DRL has already pushed four biosimilars viz, rituximab, filgrastim, darbepoetin alpha and peg-filgrastim in the market. To consolidate its position in biosimilars, DRL entered into an alliance with Merck Serono, a division of Merck KGaA, Germany during

and more »